Tvardi Therapeutics, Inc.
TVRDHealthcare|Biotechnology|US
$0.96
+0.09 (+10.79%)
DCF Value
$2.25
Tangible Book / Share
$0.86
Cash / Share
$1.68
Next Earnings Report
Nov 12, 2026
EPS est. -$0.57
Upcoming Data Readouts (2)
May 2027
Est. completion
P1P2Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708n=193
Jun 2029
Est. completion
P1Pancreatic Cancer
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT06141031n=24
Recent Press Releases
Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference
Oct 14, 2026 · GlobeNewsWire
New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)
Sep 24, 2026 · GlobeNewsWire
Tvardi Therapeutics to Participate in Upcoming Investor Events
Aug 26, 2026 · GlobeNewsWire
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Aug 14, 2026 · GlobeNewsWire